Smartlab Europe

Clinical Trials

Glenmark Announces Top-Line Results From Phase 3 Clinical Trial of Favipiravir in Patients with Mild to Moderate COVID-19

Glenmark Pharmaceuticals Ltd. a global research-led pharmaceutical company announced top-line results from a Phase 3 clinical trial in mild to moderate COVID-19 patients conducted across seven clinical sites in India. The open-label randomized, multicenter clinical trial, conducted in 150...

Lilly’s Mirikizumab Superior to Cosentyx in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis

Eli Lilly and Company announced that mirikizumab, an investigational monoclonal antibody that binds to the p19-subunit of IL23, met the primary and all key secondary endpoints versus placebo at Week 16 (superiority) and all key secondary endpoints versus Cosentyx...

SGS to provide analytical testing for AstraZenecas Covid-19 vaccine

SGS will provide its services to support the development of AstraZeneca’s Covid-19 vaccine candidate – AZD1222 – which was co-invented by the University of Oxford and its spin-out company Vaccitech. The vaccine is currently undergoing human trials in a...

Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms of COVID-19 – a critical need in the absence of a vaccine or curative treatment. Inflammation...

Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of SPINRAZA in Patients Treated with Zolgensma

Biogen Inc announced it plans to initiate a global Phase 4 clinical study, RESPOND, to examine the clinical benefit and assess the safety of SPINRAZA® (nusinersen) in infants and children with spinal muscular atrophy (SMA) who still have unmet...

Oxford COVID-19 Vaccine Shows Promise In Early Testing: Study

An experimental COVID-19 vaccine, being developed by the University of Oxford, was safe and produced an immune response in early-stage clinical trials in healthy volunteers, data showed on Monday. The vaccine, called AZD1222 and being developed by pharmaceutical company AstraZeneca...

Moderna’s COVID-19 Vaccine Soon to Enter Phase 3 Trials as Phase 1 Shows Positive Results

Moderna, an American biotech company announced on July 14 that its COVID-19 vaccine candidate is finally going to enter the final phase on July 27 as it has shown positive results in previous human trials. Undoubtedly, this is a...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »